MSD has acquired Yale University spinout Modifi Biosciences, claiming ownership of a potential new class of therapeutics for difficult-to-treat brain tumours, including glioblastomas.
France has agreed to provide temporary funding to help a clinical trial of an experimental therapy for glioblastoma, a notoriously hard-to-treat form of brain cancer, to go ahead.
In this episode of the pharmaphorum podcast series, Dr Paul Tunnah chats with Jeff Baxter, CEO of VBI Vaccines and Lee Taurman, executive vice president full service commercial at Syneos Health.
An investigator-led trial of Jazz Pharma's cannabis extract-based drug Sativex in glioblastoma – an aggressive form of brain cancer - will get underway in the UK next year.
Daiichi Sankyo has made a little bit of pharma industry history, becoming the first drugmaker to win approval in Japan for a therapy for cancer based on a virus that selectively kills malig